Gefitinib/osimertinibAcquired resistance in advanced non-small cell lung cancer: case report

被引：0

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1863卷 / 1期

关键词：

D O I：

10.1007/s40278-021-98769-7

中图分类号：

学科分类号：

摘要：

引用

页码：165 / 165

共 50 条

[1] Afatinib/gefitinib/osimertinibAcquired resistance in non-small cell lung cancer: 2 case reports
[J]. Reactions Weekly, 2019, 1741 (1) : 16 - 16
[2] OsimertinibAcquired drug resistance in non-small cell lung cancer: case report
[J]. Reactions Weekly, 2018, 1721 (1) : 226 - 226
[3] Gefitinib/osimertinibAcquired drug resistance and transformation to small cell lung cancer: case report
[J]. Reactions Weekly, 2020, 1804 (1) : 134 - 134
[4] Gefitinib/osimertinibDevelopment of resistance in non-small cell lung cancer: case report
[J]. Reactions Weekly, 2019, 1744 (1) : 138 - 138
[5] Erlotinib/gefitinib/osimertinibDevelopment of resistance in non-small cell lung cancer: case report
[J]. Reactions Weekly, 2021, 1850 (1) : 131 - 131
[6] Gefitinib for advanced non-small cell lung cancer
Sim, Esther H. A.
Yang, Ian A.
Wood-Baker, Richard
Bowman, Rayleen V.
Fong, Kwun M.
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
[7] Gefitinib in advanced non-small cell lung cancer
Sharma, R
Boyer, M
Clarke, S
Millward, M
[J]. INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
[8] OsimertinibAcquired resistance and transformation of non-small cell lung cancer to large-cell neuroendocrine carcinoma: case report
[J]. Reactions Weekly, 2021, 1848 (1) : 314 - 314
[9] Gefitinib/osimertinibAcquired resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2018, 1713 (1) : 177 - 177
[10] Gefitinib (Iressa) for advanced non-small cell lung cancer
不详
[J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1138): : 77 - 78

← 1 2 3 4 5 →